The Tirzepatide Dose-Step Tax

The dose-step tax, program by program

This is the difference between what a program charges at the starter dose and what it charges at the ceiling. It is the amount your bill rises for following the labelled titration schedule.

Why this lands at the worst possible moment

In SURMOUNT-1, mean weight reduction rose across the studied 5, 10 and 15 mg maintenance arms. The doses most likely to produce a strong response are therefore the doses a dose-scaled program charges most for. A patient responding well to escalation is a patient whose bill is rising, and the point at which many people abandon treatment is the point at which it was starting to work.

That is not an accusation of bad faith — more active drug does cost a compounder more, and dose-scaled pricing reflects a real input cost. But it inverts the incentive a patient faces, and almost no comparison table shows it, because almost every table quotes one number.

When flat pricing is the wrong choice

Flat pricing is worst value at the bottom of the ladder. If your prescriber intends to hold you at 5 mg permanently — which happens, and is a legitimate clinical decision when the response is adequate — you are paying a maintenance rate for a low dose. Several dose-scaled programs are cheaper for a patient who genuinely stays low.

The problem is that nobody knows at intake. Roughly a third of patients repeat at least one step, some stop at 7.5 mg, some run to the ceiling, and the decision belongs to a clinician who has not met you yet. Flat pricing is best understood as insurance against that uncertainty rather than as a lower price.

The arithmetic that decides it

Take the flat program's monthly price and the dose-scaled program's price at the strength you expect to maintain on. If the flat figure is lower at that strength, flat wins outright. If it is higher, multiply the difference by twelve and ask whether that sum is worth removing the risk of a bill that climbs. At the steepest program in the table above, that risk is worth $1,800 a year.

Our titration cost planner runs this against your own expected escalation pace, including repeated steps, and re-ranks the market accordingly.

What to ask before you enrol

One question settles it: what will I pay at 10 mg and at 15 mg, including every fee? A flat program answers with one number. A dose-scaled program answers with three. A program that will not answer has told you which kind it is.

The Tirzepatide Dose-Step Tax: the shortest useful summary

Tirzepatide is a once-weekly injection titrated from 2.5 mg to a 15 mg ceiling in 2.5 mg steps at intervals of at least four weeks, producing roughly 15 to 21% mean weight reduction across the studied maintenance arms at 72 weeks and about 20% against semaglutide's 14% in the only head-to-head trial. It works while it is taken; the withdrawal evidence shows substantial regain after stopping. Compounded preparations cost from $133 a month and are not FDA-approved; brand product is approved and costs considerably more.

Those five facts decide most questions people arrive with. Everything else on this page is detail underneath them — which is worth reading before you spend $2,388 on a first year, but not worth confusing with the outline.

The Tirzepatide Dose-Step Tax: where to go next

If you have not chosen a program, price your expected maintenance dose with the projector rather than reading advertisements. If you have, check what it charges at 10 mg against the price-by-dose table. If you are struggling with side effects, the side-effect reference covers each one with reported frequencies and the red flags that need a clinician. And if a program has refused to name its pharmacy, the verification walkthrough explains why that single answer outranks any price difference.